Report: Schizophrenia drug sales are shrinking, but growth will return | Pharmaceutics_R&D |

The market for schizophrenia drugs will shrink over the next couple of years, Decision Resources finds, but will bounce back after that, thanks to new drugs that can be priced at a premium to older treatments.  - September 20, 2012 | By Tracy StatonFiercePharma